Tom M. J. Evers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tom M. J. Evers has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Mashaghi
Medical Systems Biophysics and Bioengineering, Leiden Academic Centre for Drug Research, Faculty of Science, Leiden University, 2333 CC Leiden, The Netherlands
3 shared publications - Lucia Altucci
Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Vico L. de Crecchio 7, Naples, Italy
2 shared publications - Mehrad Babaei
Leiden University
2 shared publications - Antonella Toraldo
Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
1 shared publication - Antonello Mai
Sapienza University of Rome P.le Aldo Moro 5
1 shared publication - Antonio Randazzo
Department of Pharmacy, University of Naples Federico II, Naples, Italy
1 shared publication
Latest Publications
- Open Access
- 16 February 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (1) , 102861
Probing human immune cell mechanics using acoustic force spectroscopy
- 16 February 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (1) , 102861
Open AccessProbing human immune cell mechanics using acoustic force spectroscopy
- Open Access
- 27 January 2023
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 155, 106584
Biochemical reaction network topology defines dose-dependent Drug–Drug interactions
- 27 January 2023
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 155, 106584
Open AccessBiochemical reaction network topology defines dose-dependent Drug–Drug interactions
- Open Access
- 6 August 2022
- Published by Elsevier in Molecular Metabolism
- Vol. 64, 101561
Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics
- 6 August 2022
- Published by Elsevier in Molecular Metabolism
- Vol. 64, 101561
Open AccessHistone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics
- Open Access
ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response
Natural killer (NK)-cell-based immunotherapies are an attractive treatment option for cancer. We previously showed that alloreactive mouse NK cells cured mice of 4T1 breast cancer. However, the tumor microenvironment can inhibit immune responses, and these suppressive factors must be overcome to unfold the NK cells’ full anti-tumor potential. Here, we investigated the combination of antibody-dependent cellular cytotoxicity (ADDC) and the selection of KIR-HLA-ligand mismatched NK cells to enhance NK cell anti-breast cancer responses in clinically relevant settings. Donor-derived and IL-2-activated NK cells were co-cultured with patient-derived breast cancer cells or cell lines MCF7 or SKBR3 together with the anti-HER2 antibody trastuzumab. NK cells mediated anti-breast cancer cytotoxicity under normoxic and hypoxic conditions. Under both conditions, trastuzumab vigorously enhanced NK cell degranulation (CD107a) against HER2-overexpressing SKBR3 cells, but we observed a discrepancy between highly degranulating NK cells and a rather modest increase in cytotoxicity of SKBR3. Against patient-derived breast cancer cells, the anti-tumor efficacy was rather limited, and HLA class I expression seemed to contribute to inhibited NK cell functionality. KIR-ligand-mismatched NK cells degranulated stronger compared to the matched NK cells, further highlighting the role of HLA. In summary, trastuzumab and KIR-ligand-mismatched NK cells could be two strategies to potently enhance NK cell responses to breast cancer.
Open AccessADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response
Natural killer (NK)-cell-based immunotherapies are an attractive treatment option for cancer. We previously showed that alloreactive mouse NK cells cured mice of 4T1 breast cancer. However, the tumor microenvironment can inhibit immune responses, and these suppressive factors must be overcome to unfold the NK cells’ full anti-tumor potential. Here, we investigated the combination of antibody-dependent cellular cytotoxicity (ADDC) and the selection of KIR-HLA-ligand mismatched NK cells to enhance NK cell anti-breast cancer responses in clinically relevant settings. Donor-derived and IL-2-activated NK cells were co-cultured with patient-derived breast cancer cells or cell lines MCF7 or SKBR3 together with the anti-HER2 antibody trastuzumab. NK cells mediated anti-breast cancer cytotoxicity under normoxic and hypoxic conditions. Under both conditions, trastuzumab vigorously enhanced NK cell degranulation (CD107a) against HER2-overexpressing SKBR3 cells, but we observed a discrepancy between highly degranulating NK cells and a rather modest increase in cytotoxicity of SKBR3. Against patient-derived breast cancer cells, the anti-tumor efficacy was rather limited, and HLA class I expression seemed to contribute to inhibited NK cell functionality. KIR-ligand-mismatched NK cells degranulated stronger compared to the matched NK cells, further highlighting the role of HLA. In summary, trastuzumab and KIR-ligand-mismatched NK cells could be two strategies to potently enhance NK cell responses to breast cancer.